BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05141721 (GRT-C901 GRT-R902 Atezolizumab Ipilimumab… in Metastatic Colorectal Cancer): BVCT ex-ante prediction vs. reported outcome

On 26 Nov 2023, BioinvestGPT's BVCT predicted technical success and commercial failure for this trial. The 1 Apr 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant yet commercially insufficient (weak efficacy).

Clinical Trial

NCTID
NCT05141721
Acronym
GRANITE
Drug Name
GRT-C901 GRT-R902 Atezolizumab Ipilimumab Fluoropyrimidine plus leucovorin Bevacizumab
Drug MoA
modified-chimpanzee-adenoviral patient-specific neoantigen vaccine
Drug Modality
cancer vaccine
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Metastatic Colorectal Cancer
Human Patients
700
Sponsor
Gritstone bio
Phase
Phase 2 Phase 3

Prediction of , index 1344

Prospective Prediction
Prediction Index
1344
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
SUCCESS (statistically significant yet weak additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
127 days in advance
Readout Data Interpretation
weak PFS trend that's not statistically significant yet.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant yet commercially insufficient (weak efficacy)
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Phase
Phase 2, Phase 3
Status
Active not recruiting
Enrollment
700
Lead sponsor
Seattle Project Corporation
Conditions
Colorectal Neoplasms
Interventions
DRUG: GRT-C901; DRUG: GRT-R902; DRUG: Atezolizumab; DRUG: Ipilimumab; DRUG: Fluoropyrimidine plus leucovorin; DRUG: Bevacizumab
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2022-02-12
Primary completion
2027-03
Completion
2027-03
Primary outcomes
  • Phase 2: Molecular response defined as ≥ 30% decrease from baseline in circulating tumor DNA (ctDNA) (Baseline and up to 27 months)
  • Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC) (Up to 60 months)

NCT05141721 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials